Michael Macdonald, MD
Family Medicine · Brunswick, MENPI 1235220740
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $3,922 of the $5,400 with a category attached, or 72.6%. Midmark Corporation accounts for 76.0% of it on its own, with 19 other manufacturers making up the rest. Reporting peaked in 2024 at $4,148 and has fallen 99.5% since, to $23 in 2025. Among family medicine clinicians in ME with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 80 payments — averaging $67.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Midmark Corporation$4K
- AstraZeneca$270
- Pfizer$157
- Novartis$131
- GSK$127
- AbbVie$124
- plus $486 from 14 others
What the payments were for
- Travel & lodging$3,92273%
- Food & beverage$1,47827%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Midmark Corporation | 3 | $4,105 |
| AstraZeneca | 15 | $270 |
| Pfizer | 10 | $157 |
| Novartis | 8 | $131 |
| GSK | 8 | $127 |
| AbbVie(2 entities) | 6 | $124 |
| Boehringer Ingelheim | 6 | $88 |
| Novo Nordisk | 5 | $79 |
| Astellas Pharma US Inc | 4 | $66 |
| Biohaven Pharmaceuticals, Inc. | 2 | $43 |
| Merck | 3 | $39 |
| Otsuka America Pharmaceutical, Inc. | 2 | $32 |
| Johnson & Johnson | 1 | $25 |
| Hologic Sales And Service, LLC | 1 | $23 |
| Exact Sciences | 1 | $18 |
| Smith+Nephew | 1 | $17 |
| Nestle Healthcare Nutrition Inc. | 1 | $16 |
| Sanofi-aventis U.S. LLC | 1 | $15 |
| Sanofi Pasteur Inc. | 1 | $14 |
| Circassia Inc. | 1 | $11 |
How this compares
$5,400 in reported general payments places this provider in the 95th percentile of 466 family medicine providers in Maine.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 158 | $231,872 |
| EliquisApixaban | 122 | $165,628 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 80 | $110,973 |
| JanuviaSitagliptin Phosphate | 51 | $75,874 |
| OzempicSemaglutide | 67 | $61,044 |
| JardianceEmpagliflozin | 35 | $53,670 |
| FarxigaDapagliflozin Propanediol | 33 | $51,471 |
| Breo ElliptaFluticasone/Vilanterol | 46 | $41,165 |
| Bydureon BciseExenatide Microspheres | 25 | $34,651 |
| MyrbetriqMirabegron | 29 | $29,669 |
| Tresiba Flextouch U-200Insulin Degludec | 13 | $25,260 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 17 | $23,311 |
| Nurtec OdtRimegepant Sulfate | 15 | $22,563 |
| Tresiba Flextouch U-100Insulin Degludec | 17 | $20,519 |
| XareltoRivaroxaban | 11 | $18,752 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Nurtec Odt | $157 | $188,191137 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Shingrix | $127 | $166,429155 claims |
| Boehringer IngelheimJardiance, Combivent Respimat, Tradjenta | $88 | $92,44363 claims |
| MerckJanuvia, Janumet Xr | $39 | $82,79566 claims |
| AstraZenecaFarxiga, Symbicort | $270 | $64,18775 claims |
| Novo NordiskOzempic | $79 | $61,04467 claims |
| Astellas Pharma US IncMyrbetriq | $66 | $29,66929 claims |
| Johnson & JohnsonXarelto | $25 | $18,75211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 466 family medicine providers in Maine.
Other family medicine in Brunswick
- Kristy Murray-PulsiferSouth Portland$55K
- Albert HartmanLewiston$33K
- Brian KnightonFreeport$29K
- Edward YoonPortland$27K
- Jennifer FreeseVeazie$19K
- Kohar der SimonianFalmouth$18K
- Jessica Bloom FosterBangor$14K
- Cecily CannonKennebunk$14K
- Maria AtkinsPortland$14K
- Julia McDonaldAugusta$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.